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SUMMARY
Type 1 diabetes is caused by autoimmune-mediated β cell destruction leading to insulin
deficiency. The histone deacetylase SIRT1 plays an essential role in modulating several age-
related diseases. Here we describe a family carrying a mutation in the SIRT1 gene, in which all
five affected members developed an autoimmune disorder: four developed type 1 diabetes, and
one developed ulcerative colitis. Initially, a 26-year-old man was diagnosed with the typical
features of type 1 diabetes, including lean body mass, autoantibodies, T cell reactivity to β cell
antigens, and a rapid dependence on insulin. Direct and exome sequencing identified the presence
of a T-to-C exchange in exon 1 of SIRT1, corresponding to a leucine-to-proline mutation at
residue 107. Expression of SIRT1-L107P in insulin-producing cells resulted in overproduction of
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nitric oxide, cytokines, and chemokines. These observations identify a role for SIRT1 in human
autoimmunity and unveil a monogenic form of type 1 diabetes.
INTRODUCTION
Diabetes is classified into two main categories based on the clinical presentation and
pathophysiology (American Diabetes Association, 2010). Type 1 diabetes is characterized
by autoimmune β cell destruction. Conversely, type 2 diabetes is caused by a relative insulin
deficiency in the face of insulin resistance. Although polymorphisms in multiple genes have
been linked to overall susceptibility to diabetes, single gene defects leading to type 1
diabetes have been identified only in the case of AIRE and FOXP3, which are associated
with the development of complex phenotypes. Mutations in AIRE (Finnish-German
APECED Consortium, 1997; Nagamine et al., 1997) interfere with the process of immune
tolerance to self-antigens and result in autoimmune polyendocrinopahy, candidiasis,
ectodermal dystrophy (APCED). Alternatively, mutations in FOXP3 (Bennett et al., 2001)
result in defective development of regulatory T (Treg) cells, which leads to a rapidly fatal
condition called immunedysregulation, polyendocrinopathy, enteropathy, x-linked (IPEX)
syndrome. Interestingly, recent evidence suggests that SIRT1 modulates FOXP3 and thereby
influences Treg cell development, which is essential for the maintenance of immune
homeostasis and protection against autoimmunity (Beier et al., 2011; van Loosdregt et al.,
2010).
Early studies in budding yeast helped to identify sirtuin deacetylases as key enzymes that
coordinate the organism's response to calorie intake and the regulation of life span (Banks et
al., 2008; Cantó et al., 2009; Haigis and Guarente, 2006; Milne et al., 2007; Westphal et al.,
2007; Yoshizaki et al., 2009a). Subsequently, the mammalian sirtuin SIRT1 has received
much attention for its role in regulating metabolism and its role in protecting against age-
related diseases (Haigis and Sinclair, 2010). Interestingly, SIRT1 is prominently expressed
in β cells and regulates insulin secretion (Bordone et al., 2006). In mice, targeted
overexpression of SIRT1 in β cells enhances insulin secretion (Moynihan et al., 2005) and
protects from apoptosis (Tang et al., 2011). In parallel, SIRT1 also directly modulates
insulin sensitivity in peripheral tissues (Sun et al., 2007). More recently, several reports have
described a role for SIRT1 in the regulation of cytokine production (Stein et al., 2010; Yang
et al., 2010) and maintenance of T cell tolerance (Beier et al., 2011, 2012; van Loosdregt et
al., 2010; Zhang et al., 2009a). These results support a previous study demonstrating that
SIRT1-deficient mice exhibit sera-containing antibodies against nuclear antigens and
develop autoimmune conditions (Sequeira et al., 2008). Furthermore, the SIRT1 activator
Resveratrol has been shown to prevent and treat the spontaneous type 1 diabetes which
normally develops in nonobese diabetic (NOD) mice (Lee et al., 2011).
RESULTS
Description of the Patients
Type 1 diabetes was diagnosed in a 26-year-old Ashkenazi Jewish male on the basis of
hyperglycemia, a lean body mass index of 21.5 Kg/m2, signs of β cell autoimmunity
(autoantibodies to glutamic acid decarboxylase 1,150 U/L [normal value <10], islet-cell
autoantibody-2 3.0 U/L [normal value <1.5]), and insulin dependence (patient IV-2 in Figure
1A). Surprisingly, the patients' sister, father, and a paternal cousin were also diagnosed by
their endocrinologists with type 1 diabetes at the ages of 7, 12, and 15 years, respectively
(Figure 1A). All affected relatives were lean, displayed autoantibodies to β cells, lacked
measurable C-peptide levels, and required insulin injections. The autoimmune nature of the
disease was confirmed by assessing β cell antigen-specific T cell activation by peripheral
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blood mononuclear cells (Figure 1B). Interestingly, mRNA transcript and protein expression
levels for several genes involved in T cell homeostasis and regulation were decreased in Th
cells. These cells also displayed low basal and induced FOXP3 (see Figures S1A and S1B
online).
To further characterize the pathology of the index patient, an oral glucose-tolerance test was
performed 10 months after the onset of diabetes. As expected, β cell function was severely
impaired, with a blunted insulin release following stimulation by an oral glucose load
(Figure 2A). Follow-up showed that serum insulin and C-peptide concentrations steadily
decreased over time (50% decrease after 1 year, undetectable after 2 years). The patient also
presented some resistance to insulin, as revealed by a euglycemic-hyperinsulinemic clamp
study (M value 34.1 10−3 mM/min/Kg BW) and a muscle biopsy. The latter yielded
myoblasts displaying a reduced glucose uptake in response to insulin along with changes in
the phosphorylation levels of the insulin-dependent proteins, Akt, ERK, and AMPK (Figures
2B and 2C).
Identification of the Mutation
The pattern of inheritance among the affected family members was indicative of an
autosomal dominant mutation (Figure 1A). We used three different techniques in order to
identify and validate the gene(s) targeted by the inherited mutation: microsatellite
genotyping, targeted deep sequencing, and Sanger sequencing of relevant candidate genes.
All three techniques converged on a single target gene, SIRT1. Whole-genome
microsatellite analysis identified a region on chromosome 10 with a significant LOD score
of 4.0 between markers D10S210 and D10S537 corresponding to SIRT1 (Figure 3A and
Figure S2A). Although there were segments on chromosomes 4 and 22 that yielded a LOD
score of approximately 2, there were no discernible genotype-phenotype correlations for
these regions. Direct sequencing of the SIRT1 gene revealed the presence of a T-to-C
exchange in exon 1 (c.[320T > C]) present in single copy in the DNA of the affected
individuals, leading to a Leucine107Proline mutation in the SIRT1 protein (p. Leu107Pro,
Figures 3A and 3B). Based on the microsatellite analysis, exome sequencing and analysis of
specific areas from chromosomes 4, 10, and 22 were performed in three patients carrying the
mutation (patient III-1, III-4, and IV-2 in Figure 1A) and in three nonaffected subjects from
the same family (individuals IV-4, IV-5, and IV-8 in Figure 1A) and confirmed that only
this mutation segregates with the phenotype of the patients (Figure S2B). The analysis of
chromosome 10 also revealed that a SNP related to insulin activity, in KIAA1274 (Paladin),
is present in the family. However, the frequency of this SNP is high (80% homozygote in
the family and 60% in a control population), and it is equally distributed across the whole
family and independent of the phenotype (Figure S2B). Despite its lack of correlation with
the phenotype, this SNP may have helped to precipitate the observed type 1 diabetes, since it
has been proposed to inhibit insulin signaling (Huang et al., 2009). To rule out the
possibility of a common polymorphism in SIRT1, we searched for the presence of c.[320T >
C] in 100 unrelated whites, 90 Ashkenazi Jews, 160 patients with sporadic type 1 diabetes,
and 1,900 type 1 diabetes patients, with sib-pair or parent-offspring affected families. None
of these groups possessed the c.[320T > C] variant. Moreover, this mutation has not been
documented in dbSNP (http://www.ncbi.nlm.nih.gov/snp/), in 1,000 Genomes (http://www.
1000genomes.org/), or in the Exome Variant Server (http://evs.gs.washington.edu/EVS/).
This demonstrates that the exchange c.[320T > C] is not a common polymorphism.
However, there may exist other families with mutations in different regions of SIRT1 that
could lead to type 1 diabetes. Of some interest, analysis of data from a genome-wide
association study (Barrett et al., 2009) for the SIRT1 locus rs12778366 showed modest
evidence of association with type 1 diabetes (p = 0.005). This SNP is in moderate LD with
an eQTL signal for SIRT1 (D′ = 1/r2 = 0.5).
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Because type 1 diabetes has strong HLA associations with linkage to certain DQ alleles, the
HLA genotype was analyzed. The results from this analysis failed to explain the high
prevalence of the disease. Also we observed no linkage peak corresponding to the HLA
region on chromosome 6p21 (Table S1). Finally, we ruled out mutations in the six MODY
genes and in the diabetes-associated TCF7L2, IRS2, and SOCS2 genes (data not shown).
Nonaffected family members were healthy, with normal insulin secretion and action, except
for two individuals displaying features typical of type 2 diabetes (advanced age at the onset
of the disease, no insulin requirement, obesity, dyslipidemia, and hypertension; patients II-1
and III-6 in Figure 1A). All five family members carrying the mutation were diagnosed with
an autoimmune disease, while none of the 16 noncarriers tested were affected (Figure 1A).
The segregation of the mutation in the family was in complete agreement with the
phenotypes (maximal two-point lod score of 2.4; p < 0.0001 Fisher's exact test). Four
members had type 1 diabetes, including a distant member, a cousin of the patients' father.
One 18-year-old woman carrying the mutation displayed severe ulcerative colitis which
manifested at 16 years of age (patient IV-9 in Figure 1A). This patient required maintenance
therapy with the immunosuppressant azathioprine and corticosteroids (repetitively).
Increased levels of anti-nuclear antibodies (titer 1:640) and atypical ANCA (titer 1:160)
confirmed the autoimmune component of her disease.
Decreased Anti-Inflammatory Activity of SIRT1-L107P
To understand how the mutation could give rise to autoimmune defects, we tested whether
any known functions of SIRT1 were altered by the mutation. L107 lies outside of the
conserved Sirtuin enzymatic core, in a densely charged region of the protein potentially
involved in protein-protein interactions (Autiero et al., 2009a) (Figure 3C). SIRT1-L107P
showed a mild decrease in deacetylase activity relative to the wild-type protein (Figure
S3A), and there were no changes in protein stability, as assessed by a cycloheximide chase
experiment (data not shown). Additionally, mutation of L107P did not affect the subcellular
localization of SIRT1 (data not shown). In an effort to identify potential protein-protein
interactions affected by the L107P substitution, we performed immunoprecipitation
experiments with the wild-type and mutant proteins. We observed that the strongest SIRT1
interactors, identified by mass spectrometry, were not perturbed by the mutation (Figures
S3B–S3D). Furthermore, substitution of L107P did not affect the ability of SIRT1 to interact
with eIF2α or AROS (data not shown). Therefore, it is likely that protein-protein
interactions altered by the substitution are of a transient or context-specific nature.
Based on the central role attributed to cytokines and nitric oxide in the development of type
1 diabetes, and on the ability of SIRT1 to suppress nitric oxide production in β cells (Lee et
al., 2009), we analyzed the effect of SIRT1-L107P on cytokine production. Stable retroviral
transduction of the β cell line MIN6 with SIRT1-L107P led to higher cytokine-induced
nitric oxide synthase expression and increased production of nitric oxide relative to cells
expressing an equal amount of wild-type SIRT1 protein (Figure 4A and Figure S4A).
Moreover, SIRT1-L107P also led to increased expression of the cytokine TNF-α and the
chemokine KC, relative to SIRT1 wild-type controls (Figure 4A). In order to validate the
importance of SIRT1 in autoimmune destruction of β cells in vivo, we treated wild-type and
SIRT1 knockout mice with multiple low doses of streptozotocin to induce pancreatic
insulitis (Like and Rossini, 1976). Interestingly, SIRT1 knockout mice displayed increased
islet destruction along with early and marked hyperglycemia (Figure 4B). Finally,
transduction of myoblasts from healthy individuals with SIRT1-L107P resulted in insulin
resistance (Figure S4B) similar to that observed in myoblasts obtained from the index
patient (Figure 2B).
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DISCUSSION
The present work describes a monogenic form of diabetes with the typical features of type 1
diabetes (autoantibodies to β cells, lean and young at onset of hyperglycemia, rapid
disappearance of C-peptide production and insulin dependence) together with insulin
resistance. This disease appears to be the consequence of an autosomal-dominant mutation
in the SIRT1 gene. Although it is not typical to find insulin resistance in patients with type 1
diabetes, its prevalence may be underestimated (Wentworth et al., 2009). The impaired β
cell secretory function and insulin resistance we observed in patients with mutated SIRT1
gene are consistent with data from animal studies (Bordone et al., 2006; Breitenstein et al.,
2011; Moynihan et al., 2005; Sequeira et al., 2008; Sun et al., 2007; Yang et al., 2010;
Zhang et al., 2009a), which together indicate that SIRT1 may play a pivotal role in
preventing autoimmune diseases. It is tempting to speculate that the disease pathology may
arise as a combined consequence of β cell impairment and death along with subsequent
pathological activation of the immune system. Indeed, in the presence of insulin resistance,
stress may accelerate β cell death, which may result in the release of autoantigens together
with endogenous “danger signals” (alarmins) capable of promoting pathologic self-antigen
presentation (Zhang et al., 2009b). Of particular interest is the ability of SIRT1 to suppress
TNFα expression (Yoshizaki et al., 2009b) which is partially ablated by mutation of L107P.
Importantly, both type 1 diabetes and ulcerative colitis are strongly associated with this
cytokine, and TNF antagonism improves both conditions (Mastrandrea et al., 2009).
Whether or not the L107P mutation is of a dominant nature remains to be confirmed.
However, both the analysis of the family tree and the results of the in vitro studies on L107P
are suggestive of a dominant mutation. Given that the N-terminal region of SIRT1,
encompassing L107P, is thought to be involved in binding to a broad spectrum of other
proteins (Autiero et al., 2009b; Dunker et al., 2005), it is conceivable that a point mutation in
this region may change the binding affinity toward a subset of binding partners, resulting in
an apparent dominant effect.
Together, these data indicate that SIRT1 regulates immune function in humans and that a
single amino acid substitution in SIRT1 promotes hyperinflammation and metabolic
dysfunction. Molecules that enhance SIRT1 activity may be useful in treating not only this
disease but also other inflammatory or autoimmune diseases.
EXPERIMENTAL PROCEDURES
Patients and Study Procedures
We conducted the study in accordance with the ethical guidelines of the Declaration of
Helsinki II; the study design was approved by the Zurich regional and institutional review
boards. Written informed consent was obtained from all patients.
Oral glucose tolerance tests, euglycemic-hyperinsulinemic clamp studies, and muscle
biopsies were performed as described (Larsen et al., 2007).
Mutation Analysis
Genomic DNA was extracted from peripheral blood leukocytes (see the Supplemental
Information for more information).
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Induction of Autoimmune Insulitis in SIRT1 Mice
Wild-type and SIRT1-deficient mice (McBurney et al., 2003) were injected with multiple
low-dose streptozotocin as previously described (Like and Rossini, 1976). Accumulation of
lymphoid tissue in islets was assessed by histology.
Human Skeletal Muscle Cells
Human skeletal muscle cells were isolated from muscle biopsies by trypsin digestion, grown
to confluent myoblasts, and then differentiated into myotubes as previously described
(Bouzakri et al., 2003).
Plasmids and Mutagenesis
MSCV-puro containing full-length SIRT1 cDNA was subject to site-directed mutagenesis
using the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene). The following
primers were used for the mutagenesis: forward primer, 5′-
AGACAATGGGCCGGGCCCGCAGGGCCCATCT-3′; and reverse primer, 5′-
AGATGGGCCCTGCGGGCCCGGCCCATTGTCT-3′.
Retroviral Production and Infection
GP2-293 cells were cotransfected with VSVG and MSCV plasmids using FuGENE HD
transfection reagent, according to the manufacturer's instructions. Twenty hours after
transfection, the media was replaced with fresh DMEM + 10% FBS + 1X pen/strep + 1X
glutamine. Virus was harvested between 48 and 72 hr posttransfection. Cells were targeted
using filtered viral supernatants in the presence of 5 μg/mL Polybrene (Sigma). Selection
with puromycin (0.5 μg/mL) was started 48 hr later.
Cell Culture and Protein Stability Experiments
GP2-293, 293T, and NIH 3T3 were all cultured in high-glucose DMEM media with
pyruvate (GIBCO) supplemented with 10% FBS + 1X pen/strep +1X glutamine.
Cycloheximide solution (Sigma) was added to the cells to yield a final dose of 150 μg/mL
and left on the cells for the indicated amount of time. Cells were lysed for 40 min in 50 mM
Tris (pH 8), 1% NP-40, 1 mM MgCl2, 10% glycerol, and 1 mM DTT + protease inhibitor
pellet (Roche).
Immunoprecipitation of SIRT1/SIRT1-L107P and Characterization of Enzymatic Activity and
Protein Interactors
Stable 293T cells overexpressing Flag-SIRT1 or Flag-SIRT1 L107P were lysed and
subjected to immunoprecipitation using Flag-M2 agarose (Sigma). After washing, bound
protein was eluted with 3× Flag peptide (Sigma). Enzymatic activity was assayed using the
BIOMOL SIRT1-Fluor de Lys Assay. In parallel, protein complexes were analyzed by mass
spectrometry and visualized by western blot.
Production of MIN6 Cell Lines Expressing hSIRT1
MIN6B1 cells were kindly provided by Dr. Jun-ichi Miyazaki, University of Osaka
(Miyazaki et al., 1990). Cells were infected with pMSCV-SIRT1-Flag (WT), with pMSCV-
SIRT1-Flag (L107P), or with an empty virus as control. Six independent sets of WT, L107P,
and empty virus-harboring cell lines were produced. Human Sirt1 expression was analyzed
with the TaqMan real-time PCR assay and by western blotting using an anti-human SIRT1
antibody (H-300, Santa Cruz Biotechnology), an anti-mouse SIRT1 antibody (07-131,
Millipore, and an anti-FLAG antibody (A9594, SIGMA).
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To analyze the induction of iNOS, NO, KC, and TNF-α cells were treated with 1 ng/ml
mouse recombinant interleukin-1β alone or in combination with 1 ng/ml interferon-γ (R&D
Systems, Inc., Minneapolis, MN, USA). Nitrite concentration was determined using Griess
reagent. Real-time PCR data were normalized to 18 s, expressed relative to cells transduced
with empty virus, and analyzed with ANOVA and Bonferroni's multiple comparison test.
Statistical Analysis
The experimental data were analyzed with ANOVA and Bonferroni's multiple comparison
test, and the results are expressed as means ± SEM, except where noted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The Patients' Family Tree and Functional Analysis of Peripheral Blood Mononuclear
Cells
(A) Red symbols indicate family members who developed an autoimmune disease: type 1
diabetes (III-1, III-4, IV-1, IV-2) or colitis (IV-9). The yellow numbered symbols denote the
age of onset of the disease. Blue symbols indicate type 2 diabetes, while black symbols
indicate an unclear diabetes phenotype. Black numbered symbols identify all family
members who were tested for the presence of the mutation, and the letter “M” identifies the
ones who were positive. A slash denotes deceased family members. Individuals IV-1 to IV
15, III-1, III-4, III-5, III-9, III-11, and III-12 are lean (body mass index <25 Kg/m2), and II-1
and III-6 have body mass indices of 27 and >40 Kg/m2, respectively.
(B) Peripheral blood mononuclear cells were obtained from healthy control subjects (WT)
and from patients with type 1 diabetes carrying wild-type SIRT1 (DM1) or the L107P
mutation (MUT). GAD65515–528 peptide, whole GAD65 protein, and insulin elicited
antigen-specific IFN-γ production. n = 3 for each of the three groups. All data are presented
as mean ± SEM.
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Figure 2. Impaired Insulin Secretion and Sensitivity in a Patient Carrying a Mutation in the
SIRT1 Gene
(A) Plasma glucose and insulin levels during oral glucose tolerance tests of the index patient
with a SIRT1 mutation (red lines) and a control 20-year-old non-affected male family
member (green lines).
(B) Impaired insulin stimulated glucose uptake of cultured human skeletal myotubes
obtained from biopsies of the vastus lateralis muscle of the index patient with a SIRT1
mutation (diabetes) compared to the control 20-year-old nonaffected male family member
(control).
(C) The cell lysates of the myotubes were analyzed by immunoblotting with antibodies to
phosphorylated and nonphosphorylated AKT, ERK, NF-κB (p65), and AMP-K. n = 3
myotube subpopulations. All data are presented as mean ± SEM.
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Figure 3. Description of the Mutation
(A) Whole-genome microsatellite linkage analysis. Details of chromosome 10, for which the
LOD reached significance (LOD 4.1; whole-genome significance, LOD > 2.2). The length
of the chromosome is given in centimorgans (cM). According to the UniSTS database, the
region between microsatellite D10S210 and D10S537 contains the SIRT1 gene.
(B) Sanger sequence analysis of the mutation. DNA sequencing chromatograms obtained by
direct sequencing of PCR products showing the presence of the heterozygous c.[320T > C]
substitution in exon 1, not present in nonaffected members of the family and normal
individuals (control, representative example out of 200 alleles). The roman numerals
correspond to those in Figure 1A.
(C) SIRT1 gene structure and predicted protein structure.
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Figure 4. Decreased Anti-Inflammatory Activity of SIRT1-L107P
(A) MIN6 cells were stably transduced with empty, wild-type (WT), or mutant SIRT1
L107P virus and stimulated with IL-1β or a combination of IL-1β and IFN-γ. iNOS mRNA
expression relative to empty virus-transduced cells MIN6 cells, and NO formation following
cytokine stimulation expressed as fold of unstimulated cells. Findings were verified with
five separately produced sets of sirt1 WT and L107P-overexpressing cell lines each time at
least in triplicate (mean ± SD, *p < 0.05; **p < 0.01).
(B) Wild-type and SIRT1-deficient mice were injected with five daily injections of
streptozotocin (40 mg/kg). Glycemia and onset of diabetes (serum glucose >10 mM) were
monitored for 16 days. Islet histology was visualized by HE and immunostaining for insulin
(brown). The proportion of surface area that stained positive for insulin is shown. All data
are presented as mean ± SEM. *p < 0.05; n = 6 for +/+ and +/−, and n = 5 for −/−.
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